Related Experiment Video

Updated: Mar 24, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism

Chuzhong Li1, Zelin Sun, Songbai Gui

  • 1Capital Medical University, Beijing, China.

Neuro Endocrinology Letters
|August 14, 2009
PubMed
Abstract

Insights

Fulvestrant effectively suppresses prolactinoma cells by inhibiting estrogen receptor (ESR) and activating the MAPK pathway. This anti-estrogen therapy shows promise for treating pituitary tumors.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Limited understanding of anti-estrogen effects on pituitary tumors contrasts with successful breast cancer therapy.
  • Estrogen receptor (ESR) signaling is implicated in various hormone-dependent diseases.

Purpose of the Study:

  • To investigate the in vitro effects of fulvestrant, a pure anti-estrogen, on the MMQ prolactinoma cell line.
  • To elucidate the underlying molecular mechanisms of fulvestrant's action on prolactinoma cells.

Main Methods:

  • Assessed fulvestrant's impact on prolactin secretion, cell proliferation, and apoptosis in MMQ cells.
  • Quantified estrogen receptor (ESR) mRNA and protein expression.
  • Analyzed the activation of MAPK pathway proteins (ERK1/2, JNK, p38).

Main Results:

  • Fulvestrant significantly reduced prolactin secretion by up to 85.5%.
  • Demonstrated anti-proliferative effects with an IC50 of 32.4 nmol/l.
  • Induced significant apoptosis in MMQ cells.

Conclusions:

  • Fulvestrant exhibits suppressive effects on prolactinoma cells.
  • Mechanisms involve inhibition of ESR mRNA and protein expression.
  • Activation of the MAPK pathway contributes to fulvestrant's anti-tumor activity.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K